Table 2. Correlation of CXCR4 expression in tumour cells with clinicopathological patient characteristics.
| Gastric carcinoma | Patients | CXCR4 immunoreactivity of tumour cells | ||
| 0 | 1 | P | ||
| Total | 347 | |||
| Age, years | ||||
| ≤65, n (%) | 142 | 119 (84) | 23 (16) | ns (p = 0.757) |
| >65, n (%) | 151 | 124 (82) | 27 (18) | |
| Gender | ||||
| men, n (%) | 187 | 154 (82) | 33 (18) | ns (p = 0.629) |
| women, n (%) | 105 | 89 (85) | 16 (15) | |
| T category | ||||
| pT1/pT2a, n (%) | 52 | 43 (83) | 9 (17) | ns (p = 1.0) |
| pT2b/pT3/pT4, n (%) | 239 | 199 (83) | 40 (17) | |
| pT1/pT2, n (%) | 153 | 134 (88) | 19 (12) | p = 0.030 |
| pT3/pT4, n (%) | 140 | 109 (78) | 31 (22) | |
| Lymph nodes | ||||
| no metastases (%) | 74 | 60 (86) | 14 (14) | ns (p = 0.721) |
| Metastases (%) | 217 | 181 (83) | 36 (17) | |
| pN0, n (%) | 74 | 60 (86) | 14 (14) | ns (p = 0.83) |
| pN1, n (%) | 104 | 89 (86) | 15 (14) | |
| pN2, n (%) | 79 | 64 (81) | 15 (19) | |
| pN3, n (%) | 34 | 28 (82) | 6 (18) | |
| M category | ||||
| pM0, n (%) | 258 | 215 (83) | 43 (17) | ns (p = 0.633) |
| pM1, n (%) | 35 | 28 (80) | 7 (20) | |
| Grade | ||||
| G1/G2, n (%) | 78 | 69 (88) | 9 (12) | ns (p = 0.163) |
| G3/G4, n (%) | 215 | 174 (81) | 41 (19) | |
| UICC | ||||
| I, n (%) | 59 | 50 (85) | 9 (15) | ns (p = 0.1413) |
| II, n (%) | 73 | 66 (90) | 7 (10) | |
| III, n (%) | 91 | 70 (77) | 21 (23) | |
| IV, n (%) | 70 | 57 (81) | 13 (19) | |